Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine


      BACKGROUND: Very-low-calorie diets are a well established method to achieve substantial short-term weight loss in obese patients, but long-term maintenance of the weight loss is very disappointing. A combined very-low-calorie diet and pharmacologic approach could be an effective means of prolonging its benefits.
      PATIENTS AND METHODS: Eligible patients had a body-mass index greater than 30 kg/m2; those who lost 6 kg or more during a 4-week treatment with a very-low-calorie diet were randomly assigned to 1 year of treatment with sibutramine (10 mg) or identical placebo.
      RESULTS: In an intention-to-treat analysis, mean (±SD) absolute weight change at 1 year (or study endpoint) was −5.2 (±7.5) kg in the 81 patients in the sibutramine group and +0.5 (±5.7) kg in the 78 patients in the placebo group (P = 0.004). When compared with their weight at study entry (before the very-low-calorie diet), 86% of patients in the sibutramine group had lost at least 5% of their weight, compared with only 55% of those in the placebo group (P <0.001) at the study endpoint. Similarly, at month 12, 75% of subjects in the sibutramine group maintained at least 100% of the weight loss achieved with a very-low-calorie diet, compared with 42% in the placebo group (P <0.01).
      CONCLUSION: Following a very-low-calorie diet, sibutramine is effective in maintaining and improving weight loss for up to 1 year.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Van Itallie T.B
        Worldwide epidemiology of obesity.
        PharmacoEconomics. 1994; 5: 1-7
        • Bray G.A
        Complications of obesity.
        Ann Intern Med. 1985; 103: 1052-1062
        • Van Gaal L.F
        • De Leeuw I.H
        Human obesity.
        Int J Risk Safety Med. 1995; 7: 121-134
        • National task force on the prevention and treatment of obesity
        Very low-calorie diets.
        JAMA. 1993; 270: 967-974
        • Apfelbaum M
        • Bostsarron J
        • Lacatis D
        Effect of caloric restriction and excessive caloric intake on energy expenditure.
        Am J Clin Nutr. 1971; 24: 1405-1409
        • Stunkard A.J
        Current views on obesity.
        Am J Med. 1996; 100: 230-235
        • Holden J.H
        • Darga L.L
        • Olson S.M
        • et al.
        Long-term follow-up of patients attending a combination very-low calorie diet and behaviour therapy weight loss programme.
        Int J Obes. 1992; 16: 605-613
        • Pekkarinen T
        • Takala I
        • Mustajoki P
        Two year maintenance of weight loss after a VLCD and behaviour therapy for obesity.
        Int J Obes. 1996; 20: 332-337
        • Blundell J.E
        • Halford J.C.G
        Pharmacological aspects of obesity treatment.
        Int J Obes. 1995; 19: S51-S55
        • Andersen T
        • Astrup A
        • Quaade F
        Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity.
        Int J Obes. 1992; 16: 35-40
        • Szkudlarek J
        • Elsborg L
        Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet.
        Int J Obes. 1993; 17: 681-683
        • Kogon M.M
        • Kräuchi K
        • Van der Velde P
        • et al.
        Psychological and metabolic effects of dietary carbohydrates and dexfenfluramine during a low-energy diet in obese women.
        Am J Clin Nutr. 1994; 60: 488-493
        • McLean Baird I
        • Howard A.N
        A double-blind trial of mazindol using a very low calorie formula diet.
        Int J Obes. 1977; 1: 271-278
        • Finer N
        • Finer S
        • Naoumova R.P
        Prolonged used of a very low caloric diet (Cambridge diet) in massively obese patients attending an obesity clinic.
        Int J Obes. 1989; 13: 91-93
        • Finer N
        Body weight evolution during dexfenfluramine treatment after initial weight control.
        Int J Obes. 1992; 16: S25-S29
        • Inoue S
        • Egawa M
        • Satoh S
        • et al.
        Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
        Am J Clin Nutr. 1992; 55: 199S-202S
        • Heal D.J
        • Aspley S
        • Prow M.R
        • et al.
        Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
        Int J Obes. 1998; 22: S18-S28
        • Stock M.J
        Int J Obes. 1997; 21: S25-S29
        • Lean M.E.J
        Sibutramine—a review of clinical efficacy.
        Int J Obes. 1997; 21: S30-S36
        • Hanotin C
        • Thomas F
        • Jones S.P
        • et al.
        A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
        Obes Res. 1998; 6: 285-291
      1. Guy W. CGI Global Impression ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No.76388, 1976;218–228.

      2. Recommandations pour le diagnostic, la prévention et le traitement de l’obésité. AFERO, ALFEDIAM, SNDLF. Diabetes Metab. 1998;24(suppl 2):1–48.

        • Winer B.J
        Statistical Principles in Experimental Design. 2nd ed. McGraw Hill, New York1971: 261-308
        • Gillings D
        • Koch G
        The application of the principle of intention-to-treat to the analysis of clinical trials.
        Drug Informat J. 1991; 25: 411-424
      3. Jones SP, Smith IG, Kelly F, et al. Long term weight loss with sibutramine. Int J Obes. 1995;19:41. Abstract 071.

        • Goldstein D.J
        • Potvin J.H
        Long-term weight loss.
        Am J Clin Nutr. 1994; 60: 647-657
        • Nestel P.J
        • Goldrick B
        Clin Endocrinol Metab. 1976; 5: 313-335
        • Jeppesen J
        • Madsbad S
        High triglyceride, low HDL-cholesterol and risk of coronary heart disease.
        Ugeskr Laeger. 1996; 158: 6896-6901
        • Brand F.N
        • McGee D.L
        • Kannel W.B
        • et al.
        Hyperuricaemia as a risk factor of coronary heart disease.
        Am J Epidemiol. 1985; 121: 11-18
        • Freedman D.S
        • Williamson D.F
        • Gunter E.W
        • et al.
        Relation of serum uric acid to mortality and ischaemic heart disease. The NHANES I epidemiologic follow-up study.
        Am J Epidemiol. 1995; 141: 637-644
        • Wynne R.D
        • Braybrooke R.M
        • Brown T
        • et al.
        A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers.
        Int J Pharm Med. 1997; 11: 65-70